Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China via Investing.com

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) — Cytokinetics (NASDAQ:), Incorporated (Nasdaq: CYTK) today announced that Sanofi (NASDAQ:) will acquire exclusive rights to develop and market aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive…